JERUSALEM, June 2, 2015 /PRNewswire/ —
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (https://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that a scientific abstract summarizing studies performed with ORMD-0801, its orally ingestible insulin capsule on type 1 diabetic patients, will be presented at the poster sessions in the ADA 75th Scientific Sessions on June 7, 2015 in Boston. The poster will be attended by Oramed’s Chief Scientific Officer, Dr. Miriam Kidron.
Poster Presentation Details
The American Diabetes Association 75th Scientific Sessions
Abstract title: “Preprandial Oral Insulin (ORMD-0801) Reduces Rapid-Acting Insulin Requirements and Fasting Glucose Levels in T1DM Patients”
Date: Sunday, June 7, 2015
Time: 12:00-2:00pm EST
Location: The Boston Convention and Exhibition Center, Hall B
About the American Diabetes Association (ADA) Scientific Sessions
The ADA Scientific Sessions brings together over 14,000 participants with a global presence from 124 countries. The program will feature the most timely and significant advances in basic science and the prevention, diagnosis, and treatment of diabetes. For more information on the conference please visit http://professional.diabetes.org/Congress_Display.aspx?TYP=9&CID=95010.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed’s Protein Oral Delivery (POD